Ingo Volker Hartung

This study develops heterobifunctional protein binders that selectively kill specific cell types by leveraging the abundance of FKBP12, demonstrating enhanced efficacy through cellular enrichment.

This paper introduces a platform for creating tumor-targeting antibody-PROTAC conjugates that enhances bioavailability and specificity without modifying PROTACs or antibodies.